Mesothelioma from Metastatic Adenocarcinoma

Another interesting study is recognized as, -Value from the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura- by P M Cury M.D., D N Butcher, C Fisher M.D., B Corrin M.D. along with a G Nicholson D.M. – Mod Pathol 2000;13(2):107-112. Suggestions an excerpt: -Abstract – Until recently, standard approach of the majority of laboratories in distinguishing epithelioid pleural mesothelioma from metastatic adenocarcinoma has become a negative be a consequence of a panel of adeno-carcinoma-associated antibodies. However, several “mesothelium-associated” antibodies have been proposed as useful in it, and then we have applied four of these putative mesothelioma markers-thrombomodulin, cytokeratin 5/6, calretinin, and CD44H-to some 61 epithelioid pleural mesotheliomas and 63 metastatic adenocarcinomas with known primary sites (lung = 19; breast = 21; ovary = 6; colon = 10; kidney = 4; uterus, epididymis, pancreas = 1 case each). From the mesotheliomas, 55 of 61 (90%) stained for thrombomodulin, 56 of 61 (92%) for cytokeratin 5/6, 47 of 51 cases (92%) were positive for calretinin, and 39 of 43 (91%) were positive for CD44H. From the metastatic adenocarcinomas, 12 of 63 (19%) cases were positive for thrombomodulin, 9 of 63 (14%) were positive for CK5/6, and 27 of 60 (45%) were positive for CD44H. With calretinin, just one case of 59 (2%) showed positive nuclear staining. All four antibodies stained reactive mesothelium; thrombomodulin also stained endothelium; and CD44H variably stained lymphocytes, macrophages, and fibroblasts. We conclude that most of four antibodies show high sensitivity for epithelioid mesothelioma, but only calretinin (98%), cytokeratin 5/6 (86%), and thrombomodulin (81%) show sufficient specificity for practical use in this situation.-

Another interesting study is called, -Surgical treatments for pleural Mesothelioma- by PM McCormack, F Nagasaki, BS Hilaris and N Martini – The Journal of Thoracic and Cardiovascular Surgery, Vol 84, 834-842. At this point is an excerpt: -From 1939 through 1981, 170 patients were seen and treated for pleural mesothelioma. Twenty-one tumors were benign, 47 were fibrosarcomatous, and 102 were epithelioma. Resection was the chief mode of treatment in benign and fibrosarcomatous mesothelioma. Treatment of diffuse epithelial mesothelioma presented the biggest challenge. Surgical therapy, radiation therapy, and chemotherapy were utilized in combination during these patients. The overview of our patients treated prior to 1972 had shown no really benefit from including pulmonary resection inside the surgical procedure of tumors. Consequently, all patients with diffuse mesothelioma were treated by pleurectomy without pulmonary resection. Both internal and external radiotherapy were also familiar with enhance local control. Forty-nine percent of patients with epithelial mesothelioma lived 12 month. The median survival in patients whose disease was controlled by these techniques was 21 months. In spite of the poor prognosis in malignant mesothelioma, better controlled by these techniques was 21 months. .-

Another interesting study is recognized as, -RB protein status and clinical correlation from 171 cell lines representing united states, extrapulmonary small cell carcinoma, and mesothelioma.- By Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, et al. – National Cancer Institute-Navy Oncology Branch, National Cancer Institute, Bethesda, Maryland 20889. – Oncogene. 1994 Sep;9(9):2441-8. At this point is an excerpt: -Abstract – We have now studied RB protein expression in 171 cell lines produced from patients with small cell lung cancer (SCLC), non-small cell cancer of the lung (NSCLC), pulmonary carcinoid, mesothelioma, and extrapulmonary small cell cancer (EPSC) as well as have correlated this data with clinical outcome. We detected absent or aberrant RB protein expression in 66/75 SCLC, 12/80 NSCLC, 1/6 carcinoid, 0/5 mesothelioma, and 4/5 EPSC samples. Moreover, we observed integration of human papilloma virus (HPV) DNA in the single EPSC cell line that retained wildtype RB protein. We did not detect integration of HPV, SV40 or adenoviral DNA in other tumor samples with wildtype RB status. We also noted a well balanced, hypophosphorylated mutant RB in 12 SCLC and 3 NSCLC samples that might are actually falsely interpreted as wildtype by current immunohistochemical techniques. Research into the matched clinical data showed no associations between RB status and age, sex, extent of disease, performance status, smoking history, and former treatment. On top of that, retrospective analyses showed no consistent correlation of RB protein expression with either best clinical response, overall survival, possibly in vitro chemotherapeutic drug sensitivity. The stable expression of RB after gene transfection into RB(-) SCLC cells, however, ended in a trend toward increased in vitro ability to resist etoposide, cisplatin and doxorubicin.-

Many of us owe a debt of gratitude to such fine researchers. If you found some of these excerpts interesting, please look at the studies with their entirety.

Monty Wrobleski may be the author , once. To find out more please go through the following links

Depuy Hip Recall

Asbestos Disease

Related Articles – Exposure to asbestos, Asbestos, asbestos attorney, lawyer, class action lawsuit lawyers, suit, suite, lawyer, law offices, litigation, Treatment, ,

Email this short article to some Friend!

Receive Articles just like it direct in your email box!Subscribe without cost today!